IMPORTANCE OF DEFICIENCY RESPONSE IN PHARMACEUTICAL ENVIRONMENT FOR DRUG APPROVAL
This illustrates examples of series deficiencies, that’s how really company faces problem due to deficiency. It’s to convey the message if drug product manufacturer can visualize earlier all aspect of risks and manifest proactively, then there is always least chance to have the said deficiency received. However, even then if company also gets deficiency, company could have equipped with earlier data. So, what they need to do is to focus properly for addressing agency’s query by utilizing proper scientific and technical writing skills. How lack of visualization creates problem, how review cycle prolonged and how by dint of this issue approval got delayed has been clearly discussed in this case study. The reason of so many rounds of questions and review cycles become longer and finally approval got delayed is from the beginning itself agency was not satisfied or convinced with the justification given by said Company.
2. TGA regulatory framework [Internet]. 2014 [cited 2014 Oct 20]. Available from: https://www.tga.gov.au/who-we-are-what-we-do
3. TGA - The risk-based approach to regulation. Version 1.0 [Internet]. 2012 May[cited 2014 Oct 23]. Available from: https://www.tga.gov.au/tga-regulatory-framework.
4. Effective drug regulation [Internet]. 2014 [cited 2014 Nov 02]. Available from: http://apps.who.int/medicinedocs/pdf/s2300e/s2300e.pdf.
5. TGA - Impurities in drug substances and drug products [Internet]. 2014 [cited 2014 Nov 28]. Available from: https://www.tga.gov.au/book/182-related-impurities-drug-substances-and-drug-products.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The International Journal of Drug Regulatory affairs require a formal written transfer of copyright from the author(s) for each article published. We therefore ask you to complete and return this form, retaining a copy for your records. Your cooperation is essential and appreciated. Any delay will result in a delay in publication.
I/we have read and agree with the terms and conditions stated Page 2 of this agreement and I/we hereby confirm the transfer of all copyrights in and relating to the above-named manuscript, in all forms and media, now or hereafter known, to the International Journal of Drug Regulatory affairs, effective from the date stated below. I/we acknowledge that the IJDRA is relying on this agreement in publishing the above-named manuscript. However, this agreement will be null and void if the manuscript is not published in the IJDRA.
Download link for COPYRIGHT FORM